Minassian V A, Sood A K, Lowe P, Sorosky J I, Al-Jurf A S, Buller R E
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA.
J Am Coll Surg. 2000 Oct;191(4):403-9. doi: 10.1016/s1072-7515(00)00690-6.
To assess the utility and safety of three different longterm indwelling intravenous catheters in patients with gynecologic malignancies.
A retrospective review was performed of the records of all women with gynecologic malignancies who required longterm venous access catheters and ports between 1990 and 1997.
Two hundred sixty-eight women underwent placement of 308 indwelling catheters, of which 305 were available for analysis. Of those, 68 (22%) were Hickman catheters, 162 (53%) were infusaports, and 75 (25%) were Peripheral Access System (PAS) ports. Venous access was obtained percutaneously in 152 (50%) patients and by cutdown in 153 (50%). Prophylactic anticoagulation was used with 96 catheters (31%). Catheter placement was associated with 12 (4%) immediate complications and 87 (29%) delayed complications. The average duration of a catheter in place was 5.6 months for the Hickman, 12.5 months for the infusaport, and 16.0 months for the PAS port (p < 0.001). Bacteremia was more likely to develop in patients with Hickman catheters when compared with those with infusaports and PAS ports (19% versus 6% and 5%, respectively, p = 0.002). Thrombosis was significantly less likely to develop in patients receiving prophylactic anticoagulation (11% versus 4%, p = 0.004). Overall, the complication rate was lower with cutdown versus percutaneous access (p = 0.004). There was no statistically significant difference between the frequency of complications when correlated with the stage of disease, patient age, body mass index, or type of malignancy.
Infusaports and PAS ports were associated with a lower risk of infection and have a longer life than Hickman catheters. The cutdown approach was associated with a lower complication rate. Low-dose prophylactic anticoagulation should be given to all patients with longterm central venous catheters.
评估三种不同的长期留置静脉导管在妇科恶性肿瘤患者中的实用性和安全性。
对1990年至1997年间所有需要长期静脉通路导管和端口的妇科恶性肿瘤女性患者的记录进行回顾性研究。
268名女性接受了308根留置导管的置入,其中305根可供分析。其中,68根(22%)是希克曼导管,162根(53%)是输液港,75根(25%)是外周通路系统(PAS)端口。152名(50%)患者通过经皮穿刺获得静脉通路,153名(50%)患者通过切开获得。96根导管(31%)使用了预防性抗凝。导管置入与12例(4%)即刻并发症和87例(29%)延迟并发症相关。希克曼导管的平均留置时间为5.6个月,输液港为12.5个月,PAS端口为16.0个月(p<0.001)。与输液港和PAS端口的患者相比,希克曼导管患者发生菌血症的可能性更大(分别为19%、6%和5%,p=0.002)。接受预防性抗凝的患者发生血栓形成的可能性显著降低(11%对4%,p=0.004)。总体而言,切开法的并发症发生率低于经皮穿刺法(p=0.004)。与疾病分期、患者年龄、体重指数或恶性肿瘤类型相关的并发症发生率之间无统计学显著差异。
输液港和PAS端口感染风险较低,使用寿命比希克曼导管长。切开法并发症发生率较低。所有长期中心静脉导管患者均应给予小剂量预防性抗凝。